Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Peltier, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peltier, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 4:307-311, 1993
© 1993 European Society for Medical Oncology

research-article

Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC125) specific for CA125 antigen

P. Peltier1,, J.-P. Dutin2, J.-F Chatal1, P. Fumoleau2, P. Bourguet3, J.-C. Liehn4, J.-P Vuillez5, J.-Y Hérry3, A. Loboguerrero4 and the INSERM Research Network(Nantes, Rennes, Reims, Vuillejuif, Saclay)

1Service de médecine nucléaire, Centre René Gauducheau Nantes
2Service Oncologie Médicale, Centre René Gauducheau Nantes
3Service de médecine nucléaire, Centre Eugène Marquis Rennes
4Service de médecine nucléaire, Institut Jean Godinot Reims
5Service de médecine nucléaire, Hopital Albert Michalon Grenoble, France

correspondence to: Patrick Peltier, M.D. Service de medécine nucléaire Centre René Gauducheau Boulevard Jacques Monod 44805 Saint Herblain, France

BACKGROUND:: A progressive rise in serum CA 125 concentration during follow-up monitoring of ovarian cancer after treatment of primary tumor is suggestive of a recurrence.

PATIENTS AND METHODS:: A study was carried out in 19 patients with suspected recurrence of a previously treated ovarian carcinoma. All patients underwent ultrasonography (US), computed tomography (CT) and immunoscintigraphy (IS) using F(ab')2 fragments of indium-Ill-labeled OC125 monoclonal antibody (specific for CA125 antigen). The definitive diagnosis of recurrence was made on the basis of histological data obtained at surgery.

RESULTS:: In all 15 of the patients with recurrence, all three of the imaging methods had false negative results once. In 7 patients, only the IS method had positive results; six of these 7 benefited from a macroscopically total resection of the recurrence. IS was positive and concordant with US and/or CT in 7 further patients. Two of them benefited from a total resection of their recurrence. The usefulness of IS was more evident when serum CA 125 concentration was below 500 U/ml. The absence of recurrence was correctly indicated by IS and CT in 1 case and by IS associated with negative US and CT in 2 other cases. IS and CT were falsely positive in 1 case.

CONCLUSION:: Thus, immunoscintigraphy would appear to be an efficient method for detecting a recurrence early when limited involvement can make it possible for the surgeon to achieve total resection.

OC125 monoclonal antibody, immunoscintigraphy, ovarian cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
E. R. Hirvela and C. H. Organ Jr
General Surgery
JAMA, June 1, 1994; 271(21): 1674 - 1675.
[Abstract] [PDF]

Home page
 Arch SurgHome page
D. L Dunn
Monoclonal Antibodies for Diagnosis and Treatment
Arch Surg, November 1, 1993; 128(11): 1274 - 1280.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.